Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
CommuniquÚs de presse de la sociÚtÚ MERCK & CO., INC.
07/29MERCK : weighed down by charges in Q2, but drug sales rebound
AQ
07/29MERCK : Announces Appointment of Cristal N. Downing as Chief Communications & Pu..
BU
07/29MERCK : 2Q21 Merck Earnings Presentation
PU
07/29MERCK : 2Q21 Merck Other Financial Disclosures
PU
07/29MERCK & CO., INC. : Results of Operations and Financial Condition, Financial Sta..
AQ
07/29MERCK : Q2 Earnings Snapshot
AQ
07/29MERCK : Announces Second-Quarter 2021 Financial Results
BU
07/28MERCK : Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Surv..
AQ
07/28MERCK : FDA Approves KEYTRUDA for Treatment of Patients With High-Risk Early Sta..
AQ
07/27MERCK : Announces Fourth-Quarter 2021 Dividend
BU
07/27MERCK : Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Surv..
BU
07/27MERCK : FDA Approves KEYTRUDA« (pembrolizumab) for Treatment of Patients With Hi..
BU
07/23MERCK : FDA Approves KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Combinat..
AQ
07/22MERCK : FDA Approves KEYTRUDA« (pembrolizumab) Plus LENVIMA« (lenvatinib) Combin..
BU
07/21MERCK : VERQUVO« (vericiguat) Approved in the European Union
BU
07/20MERCK : Presents New Data from Ongoing Phase 2a Clinical Trial Evaluating the Sa..
BU
07/19MERCK : Announces U.S. FDA Approval of VAXNEUVANCE (Pneumococcal 15-valent Conju..
AQ
07/19PORTAGE BIOTECH CEO INTERVIEW EXPLAI : Prtg)
AQ
07/16MERCK : Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valen..
BU
07/16MERCK : KEYTRUDA (pembrolizumab) Plus Chemotherapy Before Surgery and Continued ..
AQ
07/15MERCK : KEYTRUDA« (pembrolizumab) Plus Chemotherapy Before Surgery and Continued..
BU
07/13Claus Egstrand appointed new CEO of Enzymatica
AQ
07/12MERCK : Announces Presentation of New Data from Broad HIV Program at IAS 2021
BU
07/12MERCK : Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigation..
BU
07/07MERCK : FDA Approves Expanded Indication for Merck's KEYTRUDA (pembrolizumab) in..
AQ
07/06MERCK : FDA Approves Expanded Indication for Merck's KEYTRUDA« (pembrolizumab) i..
BU
07/01MERCK : Provides Update on KEYTRUDA« (pembrolizumab) Indication in Third-Line Ga..
BU
06/30MERCK : to Hold Second-Quarter 2021 Sales and Earnings Conference Call on July 2..
BU
06/30MERCK : European Commission Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemo..
AQ
06/29ONETEN : Launches Technology Platform to Create and Enable One Million Career Op..
PR
06/29MERCK : European Commission Approves Merck's KEYTRUDA« (pembrolizumab) Plus Chem..
BU
06/25MERCK : AstraZeneca - LYNPARZA Approved in China for the Treatment of Certain Pa..
AQ
06/24MERCK : Bayer - Vericiguat approved in Japan to treat patients with chronic hear..
AQ
06/24MERCK : Appoints Michael Klobuchar Chief Strategy Officer
BU
06/24MERCK : LYNPARZA« (olaparib) Approved in China for the Treatment of Certain Pati..
BU
06/24Vaccines Market 2021 Precise Outlook- Pfizer Inc., GlaxoSmithKline plc, Merck..
AQ
06/23MERCK : Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overal..
AQ
06/22MERCK : Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overal..
BU
06/21MERCK : CONSOLIDATED STATEMENT OF INCOME - GAAP (Form 8-K)
PU
06/21MERCK & CO., INC. : Regulation FD Disclosure, Financial Statements and Exhibits ..
AQ
06/17MERCK : to Participate in the Guggenheim Biopharma Strategy Series
BU
06/16MERCK : Announces the Kenneth C. Frazier Award for Maternal Health Equity to Acc..
BU
06/09Campbell Soup, Comtech fall; Merck, Vertex rise
AQ
06/09MERCK : Announces Supply Agreement with U.S. Government for Molnupiravir, an Inv..
BU
06/08MERCK : New data on keytruda (pembrolizumab) plus lenvima (lenvatinib) versus su..
AQ
06/07MERCK : MSD Animal Health to Acquire Assets of LIC Automation Ltd.
BU
06/07MERCK : New Data on KEYTRUDA« (pembrolizumab) Plus LENVIMA« (lenvatinib) Versus ..
BU
06/04MERCK : KEYTRUDA (pembrolizumab) Given After Surgery Reduced the Risk of Disease..
AQ
06/04MERCK : LYNPARZA (olaparib) reduced the risk of cancer recurrence by 42% in the ..
AQ
06/03MERCK : LYNPARZA« (olaparib) Reduced the Risk of Invasive Disease Recurrence or ..
BU
06/03MERCK : KEYTRUDA« (pembrolizumab) Given After Surgery Reduced the Risk of Diseas..
BU
06/03MERCK & CO., INC. : Completion of Acquisition or Disposition of Assets, Financia..
AQ
06/03MERCK : Announces Completion of Organon & Co. Spinoff
BU
06/01MERCK : and Sanofi's First and Only Six-in-One Pediatric Combination Vaccine Now..
BU
05/28MERCK : Vote Results
PU
05/27MERCK : Organon Set to Join S&P 500; HollyFrontier to Join S&P MidCap 400; Servi..
PR
05/27MERCK & CO., INC. : Submission of Matters to a Vote of Security Holders (form 8-..
AQ
05/25MERCK : Announces Third-Quarter 2021 Dividend
BU
05/24MERCK : Receives Positive EU CHMP Opinion for KEYTRUDA« (pembrolizumab) in Combi..
BU
05/21MERCK : Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PN..
AQ
05/20MERCK : Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PN..
BU
05/18Astellas to Present Data from Expanding Oncology Portfolio During the 2021 AS..
AQ
05/17MERCK : Gabrielle Union-Wade Joins 'Don't Skip' Campaign to Encourage Doctor Wel..
PR
05/13MERCK : Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-F..
BU
05/07MERCK : Declares Record Date and Dividend for the Organon & Co. Spinoff
BU
05/07EISAI : and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review ..
AQ
05/06MERCK : Notice to Directors and Executive Officers, dated May 5, 2021
PU
05/06MERCK : FDA Approves Merck's KEYTRUDA (pembrolizumab) Combined With Trastuzumab ..
AQ
05/06MERCK : Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than ..
BU
05/06MERCK : and Eisai Receive Priority Review From FDA for KEYTRUDA« (pembrolizumab)..
BU
05/05MERCK & CO., INC. : Temporary Suspension of Trading Under Registrant's Employee ..
AQ
05/05MERCK : & CO., INC. Management's Discussion and Analysis of Financial Condition ..
AQ
05/05MERCK : FDA Approves Merck's KEYTRUDA« (pembrolizumab) Combined With Trastuzumab..
BU
05/04MERCK : Hosts Organon Investor Day Outlining New Company's Vision, Focus and Bus..
AQ
05/04MERCK : Federal Court Upholds Health Canada's Strict Interpretation Of Patent Li..
AQ
1  2  3  4  5  6  7  8  9  10Next
Official Publications
05/25Dividends 
05/11Report 
05/06Report 
05/05SEC Filing 10Q-1 
04/29SEC Filing 8K 
04/291st quarter results 
Upcoming event on MERCK & CO., INC.